07/21/2021 12:59 PM
Clarín.com
Society
Updated 07/21/2021 12:59 PM
With the advancement of new variants, researchers are trying to determine how different vaccines can cope with these coronavirus mutations.
Now, a study evaluated what happens with
the Delta strain and Sinopharm
, one of the vaccines that are being applied massively at this stage of the vaccination campaign in Argentina.
And they found that although it generates
strong protection
, the immune response is lower than against the original strain.
This study,
the first to evaluate Sinopharm against Delta
, has not yet been published in any peer-reviewed journal but has been published on the MedRxiv site, a platform where unpublished research is uploaded that will later be validated in scientific journals.
The research was carried out by scientists from the University of Sri Jayewardenepura, in Sri Lanka, the Municipal Council of Colombo (another city in the Asian country) and the University of Oxford.
The study was conducted in 282 people, and the authors indicated that the Chinese vaccine achieved a
95%
antibody response (seroconversion)
against the SARS-CoV-2 spike protein
.
However, according to information released by Reuters, those who received the Sinopharm vaccine had
a 1.38 reduction in their immune response
against Delta compared to the original Wuhan strain.
Regarding the Beta variant, previously called South African, the reduction in antibody levels is more pronounced, 10 points.
But the researchers noted that
there are no differences
in antibody levels to the two variants between people vaccinated with Sinopharm and those who had been naturally infected with SARS-CoV-2, suggesting that the vaccine induces
a similar antibody response. having had Covid
.
For Neelika Malavige, head of the department of Immunology at the University of Sri Jayewardenepura, “the conclusion of this research is that when we talk about Delta and other variants, the Sinopharm vaccine induces similar responses as naturally infected people,
which is very good.
”.
“Among the groups aged 20 to 40 years, 98% developed antibodies, while in the group over 60, 93% did.
This is not surprising because older people respond less to vaccines ”, added the specialist.
So far, Sinopharm is
the vaccine that Argentina received the most doses
.
This Tuesday, a shipment of another 768,000 doses arrived in Ezeiza, and there are already 12,144 million that have arrived in the country.
Thus, China displaced Sputnik at the top of the basket of vaccines, of which just over 11.86 million have arrived so far, most of the first component.
ACE
Look also
Vaccination for people over 18 to 24 was enabled in the City: how to sign up
One by one, the news about vaccination against Covid in the Province of Buenos Aires